Chartsbank is a comprehensive database containing information on more than 3000 new drugs in development, inclusive of pre-clinical research up to phase IV development

Subscribers view details.


 
Please Select Filter Criteria for the drug pipeline
Drug Pipeline by drug name:
Drug Pipeline by Company:
Drug Pipeline by Disease:

Subscribe

Drug Pipeline by Generic :
Drug Pipeline by Current Status:
Drug Pipeline by ICN:

...81828384858687888990...
CompanyDrug NameStatusIndication Group
UCB Pharma No drug name discontinuedGenito urinary system & sex hormones
Lilly No drug name accomplished Phase IIGenito urinary system & sex hormones
Threshold No drug name discontinuedGenito urinary system & sex hormones
OSI No drug name accomplished Phase IIAntineoplastic & immunomodulating agents
Exelixis No drug name in Phase IIIAntineoplastic & immunomodulating agents
Repligen No drug name accomplished Phase IINervous system
Novartis No drug name in Phase IIINervous system
Allergopharma Joachim Ganzer KG No drug name in Phase IIAntineoplastic & immunomodulating agents
Allergopharma Joachim Ganzer KG No drug name in Phase IIIAntineoplastic & immunomodulating agents
OSI No drug name discontinuedAntineoplastic & immunomodulating agents
Genzyme No drug name in Phase IIAntineoplastic & immunomodulating agents
Salmedix No drug name in Phase IIAntineoplastic & immunomodulating agents
Sosei No drug name in Phase IIIAntineoplastic & immunomodulating agents
Roche No drug name in Phase IIAntineoplastic & immunomodulating agents
Medarex No drug name in Phase IIIAntineoplastic & immunomodulating agents
Micromet AG No drug name in Phase IIAntineoplastic & immunomodulating agents
Roche No drug name in Phase IAntineoplastic & immunomodulating agents
Takeda No drug name discontinuedAntineoplastic & immunomodulating agents
Wyeth No drug name discontinuedAntineoplastic & immunomodulating agents
Antisoma No drug name accomplished Phase IAntineoplastic & immunomodulating agents
...81828384858687888990...




Drug Pipeline Copyright © 2005- 2017 All Rights Reserved.